Liposome Technology, Inc.

Sequus Pharmaceuticals, Inc.

Alza Corporation

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Acrotech Biopharma Inc.

Robert M Abra

Ramachandran Radhakrishnan

Paul J Mihalko

Francis C Szoka, Jr

Karen Reis

Yechezkel Barenholz

Yuanpeng Zhang

William T Monte

Luke S Guo

Danilo D Lasic

Bing Luo

Tal Peleg-Shulman

Disclosed herein are various compositions comprising neoplastic formulations and their methods of use.

Ready-to-use formulation for Vincristine Sulfate Liposome Injection

A liposome composition having a compound entrapped in a supersaturated solution and method for preparing such a composition are described.

Liposomes containing an entrapped compound in supersaturated solution

A liposome composition containing an entrapped cisplatin compound is described. The liposomes have a surface coating of hydrophilic polymer chains on inner and outer surfaces and an entrapped cisplatin compound. The compound is entrapped with substantially greater retention in the liposomes, when compared to liposomes lacking the polymer coating. A method of preparing the composition is also described.

Liposomes containing a cisplatin compound

A method and system for treating bronchial constriction. The system includes a liposome composition containing a .beta..sub.2 -adrenoreceptor agonist in a liposome-entrapped form, and a device for aerosolizing a metered quantity of the composition. The drug in liposome aerosol form is substantially more effective in bronchodilation, over a substantially longer time, than the same amount of drug in free-drug aerosol form.

Liposome/bronchodilator method & System

An amphotericin B composition containing particles of amphotericin B and cholesterol sulfate, in a molar ratio of between about 1:1 to 2:1. The particles, when stored in lyophilized form and reconstituted in an aqueous suspension, have particle sizes predominantly between about 50-250 nm. The composition has stable particle sizes in an aqueous suspension over a several-day storage period. The composition is significantly less toxic and more effective in treating fungal infection than prior amphotericin B formulations.

Amphotericin B/cholesterol sulfate composition and method

A method for delivering a therapeutic dosage of corticosteroid drug to the lungs, for treating a lung condition or disease. An aqueous suspension of sized liposomes containing the drug in liposome-entrapped form is aerosolized under conditions which produce aerosol particle sizes favoring particle deposition in a selected region of the respiratory tract, and the aerosol is administered in an amount which delivers the thereapeutic dosage level to the selected lung region.

Corticosteroid inhalation treatment method

A method of administering a liposome/amphotericin B composition having a predetermined size distribution in 0.2-0.5 micron size range. The method includes preparing a suspension of heterogeneously sized amphotericin B liposomes in an aqueous solution containing at least about 0.5% w/v of membrane-stabilizing agent. After sizing to the desired size distribution, and before the liposome sizes change substantially, the suspension is lyophilized for storage. After reconstituting the lyophilized material, the resulting suspension is administered before a substantial size changes in the liposomes occur.

Stabilized liposome/amphotercin B composition and method

An amphotericin B composition containing particles of amphotericin B and cholesterol sulfate, in a molar ratio of between about 1:1 to 1:4. The particles, when stored in lyophilized form and reconstituted in an aqueous suspension, have particle sizes predominantly between aobut 100-400 nm. The composition formed at a molar ratio of about 1:1 amphotericin B:cholesterol sulfate has stable particle sizes in an aqueous suspension over a several-day storage period. The composition is significantly less toxic and more effective in treating fungal infections than prior amphotericin B formulations.

Method for treating fungal infections with amphotericin B/cholesterol

A system and method for administering a drug, at a selected dose, via the respiratory tract. Spray-dried liposome particles containing the selected dose of the entrapped drug are released into the air in aerosolized form, either by entrainment in an air or propellant stream, or by release from a pressurized can containing a suspension of the liposomes in a fluorchlorocarbon solvent.

Method and apparatus for administering dehydrated liposomes by inhalation

An amphotericin B composition containing particles of amphotericin B and cholesterol sulfate, in a molar ratio of between about 1:1 to 1:4. The particles, when stored in lyophilized form and reconstituted in an aqueous suspension, have particle sizes predominantly between about 100-400 nm. The composition formed at a molar ratio of about 1:1 amphotericin B:cholesterol sulfate ahs stable particle sizes in an aqueous suspension over a several-day storage period. The composition is significantly less toxic and more effective in treating fungal infection than prior amphotericin B formulations.

Amphotericin B/cholesterol sulfate composition

A dehydrated liposome/amphotericin B composition which, upon addition of an aqueous medium, forms a suspension of liposomes (a) having a predetermined size distribution in size range less than about 1 micron, and (b) containing at least about 1 mole percent amphotericin B. The composition is prepared by forming a suspension of heterogeneous size amphotericin B liposomes in an aqueous solution containing at least about 0.5% of a membrane-stabilizing agent. The suspension is sized--for example, by extrusion through a small-pore polycarbonate membrane--to produce liposomes having the selected size distribution, and dehydrated.

Growing community of inventors

San Francisco, CA, United States of America

Robert M Abra